Currently, there are 338.84M common shares owned by the public and among those 226.75M shares have been available to trade.
The company’s stock has a 5-day price change of 7.26% and 33.51% over the past three months. NUVB shares are trading -5.64% year to date (YTD), with the 12-month market performance down to -10.36% lower. It has a 12-month low price of $1.54 and touched a high of $3.97 over the same period. NUVB has an average intraday trading volume of 3.62 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 10.11%, 19.17%, and 3.73% respectively.
Institutional ownership of Nuvation Bio Inc (NYSE: NUVB) shares accounts for 48.62% of the company’s 338.84M shares outstanding.
It has a market capitalization of $854.06M and a beta (3y monthly) value of 1.38. The earnings-per-share (ttm) stands at -$2.34. Price movements for the stock have been influenced by the stock’s volatility, which stands at 0.70% over the week and 4.46% over the month.
Analysts forecast that Nuvation Bio Inc (NUVB) will achieve an EPS of -0.14 for the current quarter, -0.16 for the next quarter and -0.59 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.14 while analysts give the company a high EPS estimate of -0.14. Comparatively, EPS for the current quarter was -1.85 a year ago. Earnings per share for the fiscal year are expected to increase by 69.68%, and 1.43% over the next financial year. EPS should grow at an annualized rate of 37.79% over the next five years, compared to -49.14% over the past 5-year period.
Looking at the support for the NUVB, a number of firms have released research notes about the stock. Citizens JMP stated their Mkt Outperform rating for the stock in a research note on April 23, 2025, with the firm’s price target at $6. Jefferies coverage for the Nuvation Bio Inc (NUVB) stock in a research note released on March 27, 2024 offered a Buy rating with a price target of $10. BTIG Research was of a view on March 26, 2024 that the stock is Buy, while Jefferies gave the stock Hold rating on January 06, 2023, issuing a price target of $5- $2. BTIG Research on their part issued Neutral rating on August 02, 2022.
